Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Chemotherapy has long been a standard treatment for a wide range of malignancies, where patients typically undergo multiple rounds of chemotherapy regimens to control tumor growth. In the clinic, the chemotherapy drugs cyclophosphamide and fludarabine are commonly used prior to Chimeric Antigen Rece...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140541/full |
| _version_ | 1827998141508485120 |
|---|---|
| author | Arthur Xuan Wang Xiao Jing Ong Criselle D’Souza Criselle D’Souza Paul J. Neeson Paul J. Neeson Joe Jiang Zhu Joe Jiang Zhu |
| author_facet | Arthur Xuan Wang Xiao Jing Ong Criselle D’Souza Criselle D’Souza Paul J. Neeson Paul J. Neeson Joe Jiang Zhu Joe Jiang Zhu |
| author_sort | Arthur Xuan Wang |
| collection | DOAJ |
| description | Chemotherapy has long been a standard treatment for a wide range of malignancies, where patients typically undergo multiple rounds of chemotherapy regimens to control tumor growth. In the clinic, the chemotherapy drugs cyclophosphamide and fludarabine are commonly used prior to Chimeric Antigen Receptor T (CAR-T) cell therapy to lymphodeplete and improve CAR-T cell engraftment. In this review, we discuss the use of chemotherapy in combination with CAR-T cell therapy. We also show that chemotherapy can deplete immunosuppressive cells, promote a pro-inflammatory tumor microenvironment, disrupt tumor stroma, and improve CAR-T cell recruitment to the tumor. Although the combination of chemotherapy plus CAR-T cell therapy is promising, certain aspects of chemotherapy also pose a challenge. In addition, the combined therapeutic effect may be heavily dependent on the dose and the treatment schedule. Thus, we also discussed the obstacles to effective clinical outcomes of the combination therapy. |
| first_indexed | 2024-04-10T05:40:18Z |
| format | Article |
| id | doaj.art-b8ced054c3af4a1b9a2a8acd5aac63df |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:40:18Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b8ced054c3af4a1b9a2a8acd5aac63df2023-03-06T11:17:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11405411140541Combining chemotherapy with CAR-T cell therapy in treating solid tumorsArthur Xuan Wang0Xiao Jing Ong1Criselle D’Souza2Criselle D’Souza3Paul J. Neeson4Paul J. Neeson5Joe Jiang Zhu6Joe Jiang Zhu7Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, VIC, AustraliaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaSir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, VIC, AustraliaChemotherapy has long been a standard treatment for a wide range of malignancies, where patients typically undergo multiple rounds of chemotherapy regimens to control tumor growth. In the clinic, the chemotherapy drugs cyclophosphamide and fludarabine are commonly used prior to Chimeric Antigen Receptor T (CAR-T) cell therapy to lymphodeplete and improve CAR-T cell engraftment. In this review, we discuss the use of chemotherapy in combination with CAR-T cell therapy. We also show that chemotherapy can deplete immunosuppressive cells, promote a pro-inflammatory tumor microenvironment, disrupt tumor stroma, and improve CAR-T cell recruitment to the tumor. Although the combination of chemotherapy plus CAR-T cell therapy is promising, certain aspects of chemotherapy also pose a challenge. In addition, the combined therapeutic effect may be heavily dependent on the dose and the treatment schedule. Thus, we also discussed the obstacles to effective clinical outcomes of the combination therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140541/fullchemotherapyChimeric Antigen Receptor T cell (CAR-T)solid tumortumor microenvironment (TME)personalized combination |
| spellingShingle | Arthur Xuan Wang Xiao Jing Ong Criselle D’Souza Criselle D’Souza Paul J. Neeson Paul J. Neeson Joe Jiang Zhu Joe Jiang Zhu Combining chemotherapy with CAR-T cell therapy in treating solid tumors Frontiers in Immunology chemotherapy Chimeric Antigen Receptor T cell (CAR-T) solid tumor tumor microenvironment (TME) personalized combination |
| title | Combining chemotherapy with CAR-T cell therapy in treating solid tumors |
| title_full | Combining chemotherapy with CAR-T cell therapy in treating solid tumors |
| title_fullStr | Combining chemotherapy with CAR-T cell therapy in treating solid tumors |
| title_full_unstemmed | Combining chemotherapy with CAR-T cell therapy in treating solid tumors |
| title_short | Combining chemotherapy with CAR-T cell therapy in treating solid tumors |
| title_sort | combining chemotherapy with car t cell therapy in treating solid tumors |
| topic | chemotherapy Chimeric Antigen Receptor T cell (CAR-T) solid tumor tumor microenvironment (TME) personalized combination |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140541/full |
| work_keys_str_mv | AT arthurxuanwang combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT xiaojingong combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT criselledsouza combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT criselledsouza combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT pauljneeson combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT pauljneeson combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT joejiangzhu combiningchemotherapywithcartcelltherapyintreatingsolidtumors AT joejiangzhu combiningchemotherapywithcartcelltherapyintreatingsolidtumors |